<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652571</url>
  </required_header>
  <id_info>
    <org_study_id>848016005</org_study_id>
    <secondary_id>NL62932.068.17 / METC173051</secondary_id>
    <secondary_id>2017-003307-21</secondary_id>
    <nct_id>NCT03652571</nct_id>
  </id_info>
  <brief_title>Nortriptyline for the Treatment of Functional Dyspepsia</brief_title>
  <acronym>TENDER</acronym>
  <official_title>Tailored Treatment of Functional Dyspepsia With Nortriptyline: a Multi-center Double-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional dyspepsia (FD) is a common functional gastrointestinal disorder characterized by
      upper abdominal discomfort/pain and/or symptoms of meal-related fullness/satiety. There is
      currently no definitive therapy that is beneficial for all FD patients. Accumulating evidence
      suggests efficacy of tricyclic antidepressants (TCAs) in FD. However, no firm conclusion can
      be drawn currently due to the relatively small amount of studies and large heterogeneity
      between studies. In addition, TCAs are often associated with side effects, which occur early
      after initiation of therapy preceding the therapeutic effect and often result in
      discontinuation of the therapy. These side effects are related to drug metabolism, which
      depend on polymorphisms of the cytochrome P (CYP) enzyme system. It is therefore hypothesized
      that pre-treatment assessment of CYP genotype and subsequent exclusion of abnormal
      metabolizers limits the occurrence of side-effects and as such improves compliance and
      efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response to therapy, as defined by a 30% reduction from baseline (i.e. the run-in period) in the weekly average of daily symptom scores, during at least 50% of weeks 3-12 of treatment. Symptoms will be assessed daily using a digital diary (mobile phone application). Recorded symptoms include the five core symptoms of FD: epigastric pain, epigastric burning, postprandial fullness, early satiety and upper abdominal bloating.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adequate relief</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-reported adequate relief. Adequate relief is defined as a 'yes' response in at least 50% of weeks 3-12 of the treatment. Reported via digital diary (mobile phone application)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life</measure>
    <time_frame>12 weeks, 3 &amp; 6 months</time_frame>
    <description>Assessed with the use of the Euro-Qol-5D (EQ-5D; change from baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspepsia-specific quality of life</measure>
    <time_frame>12 weeks, 3 &amp; 6 months</time_frame>
    <description>Dyspepsia-specific quality of life, assessed with the use of the Nepean Dyspepsia Index (NDI; change from baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility</measure>
    <time_frame>12 weeks, 3 &amp; 6 months</time_frame>
    <description>Cost-utility, as determined by calculations incorporating total treatment costs and changes in EQ-5D-5L (QALYs gained), and results from the Medical Consumption Questionnaire (MCQ) and Productivity Cost Questionnaire (PCQ) [savings from reduced medical resource use and increased work productivity respectively].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication.</measure>
    <time_frame>12 weeks</time_frame>
    <description>As reported via digital diary (mobile phone application)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of side effects.</measure>
    <time_frame>12 weeks</time_frame>
    <description>As reported via digital diary (mobile phone application)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rates following discontinuation</measure>
    <time_frame>6 months</time_frame>
    <description>Responder rates following discontinuation of treatment at 6 months follow-up, as defined by a &quot;Yes&quot; to the query regarding adequate relief from baseline symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative mood - anxiety</measure>
    <time_frame>12 weeks, 3 &amp; 6 months</time_frame>
    <description>Assessed with the use of the Generalized Anxiety Disorder-7 (GAD-7; change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative mood - depression</measure>
    <time_frame>12 weeks, 3 &amp; 6 months</time_frame>
    <description>Assessed with the use of the Patient Health Questionnaire-9 (PHQ-9; change from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Nortriptyline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nortriptyline in an escalating dose regimen:
Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nortriptyline</intervention_name>
    <description>Nortriptyline escalating dose regimen:
Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg</description>
    <arm_group_label>Nortriptyline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years;

          -  A diagnosis of FD according to the Rome IV criteria;

          -  Predicted CYP2D6 extensive metabolizer phenotype on the basis of CYP genotyping

          -  Insufficient effect of first line treatment with proton pump inhibitors (twice daily)
             or prokinetics;

          -  In the presence of alarm symptoms, patients are required to have undergone an upper
             gastrointestinal endoscopy (without evidence of organic disease), and have tested
             negative for Helicobacter pylori 2 years prior to inclusion;

          -  Women in their fertile age (&lt;55 years old) must use contraception or be postmenopausal
             for at least two years.

        Exclusion Criteria:

          -  Predicted CYP2D6 poor, intermediate or ultrarapid metabolizer phenotype on the basis
             of CYP genotyping

          -  Evidence of current anxiety and/or depression disorder as defined by a score â‰¥ 10 on
             the GAD-7 and/or PHQ-9 questionnaire;

          -  Current use or any previous use of psychotropic medication in the last 3 months prior
             to inclusion;

          -  Inability to discontinue prokinetics, NSAIDs or opioids;

          -  Using drugs of abuse;

          -  Using more than 2 or 3 units of alcohol per day (females and males respectively)

          -  Previous major abdominal surgery or radiotherapy interfering with gastrointestinal
             function:

               1. Uncomplicated appendectomy, cholecystectomy and hysterectomy allowed unless
                  within the past 6 months;

               2. Other surgery upon judgment of the principle investigator;

          -  History of gastric ulcer;

          -  History of liver disease, cholangitis, achlorhydria, gallstones or other diseases of
             the gallbladder/biliary system;

          -  History of epilepsy

          -  History of glaucoma

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ad A.A.M Masclee, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bram Beckers, MD</last_name>
    <phone>0031 43 388 1844</phone>
    <email>tender-intmed@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Keszthelyi, MD, PhD</last_name>
    <email>daniel.keszthelyi@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A.J. Bredenoord</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R.J.F Felt-Bersma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D.P. Hirsch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>K van Hee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.J.M Witteman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.J. Kolkman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L.A. van der Waaij</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi Hilversum</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.D.J. van den Elzen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H.J.A. Jebbink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne ziekenhuis</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C.H.M. Clemens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastrich University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Keszthelyi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bernhoven</name>
      <address>
        <city>Uden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B.J.T. Haarhuis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A.H. Oberndorff-Klein Woolthuis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MMC</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.W.A. Straathof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

